New Schizophrenia Drug Cobenfy Priced Out of Reach for Many Israelis
Summarized from Ynetnews by baba
A new schizophrenia drug, Cobenfy, approved in the U.S. in September 2024, offers a novel treatment approach but costs approximately $2,500 in Israel, making it unaffordable for many. Families like Yuki's, whose son has lived with schizophrenia for decades, face significant challenges with existing treatments' side effects and high costs. While the drug's unique mechanism shows promise in clinical trials, its inclusion in Israel's national health benefits package is pending, highlighting broader issues of underfunding in the country's mental healthcare system.
The story in 6 lines · by baba
- New schizophrenia drug Cobenfy offers a novel treatment mechanism but costs around $2,500 in Israel.
- Cobenfy's unique approach targets muscarinic receptors, differing from traditional dopamine-blocking antipsychotics.
- Families of individuals with schizophrenia face significant financial barriers to accessing advanced treatments.
- Israel's mental healthcare system is underfunded, receiving only about 6% of public healthcare spending.
- Advocacy groups are pushing for Cobenfy's inclusion in Israel's national health benefits package.
- Older schizophrenia medications can cause severe side effects, impacting patients' quality of life and ability to work.
Ynetnews publishes in English. The key points are summarized above. Read Ynetnews’s full report from the link at the top of the page.
